Details of Disease

General Information of Disease (ID: DIS0RYDF)

• Disease Name: Ocular inflammation
• Disease Class: 9C61: Glaucoma
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DIS0RYDF: Ocular inflammation
• ICD Code:
  ICD-11: ICD-11: 9C61.24
  ICD-10: ICD-10: H40.4
  ICD-9: ICD-9: 370.33
  Expand ICD-9: 370.33

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Besifloxacin	DMPHXMI	Approved	Small molecular drug	[1]

This Disease is Treated as An Indication in 5 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Rivoglitazone	DMBY31K	Phase 3	Small molecular drug	[2]
NT-501	DM4H78P	Phase 2/3	NA	[3]
OT-551	DMTNOXQ	Phase 2	Small molecular drug	[4]
SYL-045001	DMH90C4	Phase 2	NA	[5]
Epithalon	DMWSGZU	Phase 1/2	Small molecular drug	[6]

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
SCY-641	DMELFBU	Preclinical	NA	[7]

This Disease is Treated as An Indication in 4 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AM-679	DMBMVT6	Investigative	Small molecular drug	[8]
AP-1600	DMB5S3K	Investigative	NA	[8]
LC-01	DMJAX91	Investigative	NA	[8]
Suprofenac	DMQTUEI	Investigative	NA	[8]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [2] ClinicalTrials.gov (NCT00571519) Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT00447980) A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa. U.S. National Institutes of Health.
• [4] ClinicalTrials.gov (NCT00306488) OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT02455999) Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular Pain.
• [6] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021226)
• [7] 2011 Pipeline of SCYNEXIS.
• [8] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.